SCHEMBL7797088

SCHEMBL7797088

CN(Cc1ccccc1)NC(=O)OC(C)(C)C

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 3/20 0.63
CTSS P25774 4/20 0.59
CTSL P07711 3/20 0.59
CTSB P07858 3/20 0.59
CA12 O43570 2/20 0.51
CA1 P00915 1/20 0.51
CA7 P43166 1/20 0.51
CA14 Q9ULX7 1/20 0.51
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
ATM Q13315 1/20 0.47
RIPK1 Q13546 1/20 0.46
IDO1 P14902 1/20 0.46
CTSK P43235 1/20 0.45
CA9 Q16790 1/20 0.45
HDAC3 O15379 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC2 Q92769 1/20 0.44
NCOR2 Q9Y618 1/20 0.44
PPARG P37231 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL506498 0.89 AKT1 (0.52) AKT1CTSSCTSLCTSBPPARG
SCHEMBL4748453 0.83 AKT1 (0.62) AKT1CTSSCTSLCTSBCA12
SCHEMBL8532390 0.81 SMN1; SMN2 (0.56) CTSSCTSLCTSBCA12CA1
SCHEMBL9098649 0.80 AKT1 (0.71) AKT1CTSSCTSLCTSBCA12
SCHEMBL7472970 0.79 CTSS (0.62) AKT1CTSSCTSLCTSBCA12
SCHEMBL19742566 0.79 CTSL (0.57) AKT1CTSSCTSLCTSBCA12
SCHEMBL19742676 0.79 AKT1 (0.54) AKT1CTSSCTSLCTSBCA12
SCHEMBL4254558 0.79 CTSL (0.57) AKT1CTSSCTSLCTSBCA12
SCHEMBL9756736 0.78 AKT1 (0.53) AKT1CTSSCTSLCTSBCA12
SCHEMBL4246507 0.78 AKT1 (0.53) AKT1CTSSCTSLCTSBCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110105389-A1 Macrocyclic Ghrelin Receptor Antagonists and Inverse Agonists and Methods of Using the Same OCERA THERAPEUTICS, INC. 2011-05-05 US disclosed
WO-2011053821-A1 MACROCYCLIC GHRELIN RECEPTOR ANTAGONISTS AND INVERSE AGONISTS AND METHODS OF USING THE SAME TRANZYME PHARMA, INC. (US) 2011-05-05 WO disclosed
US-20010007869-A1 ALPHA-SUBSTITTUTED PYRIDAZINO QUINOLINE COMPOUNDS SYNGENTA LIMITED (GB) 2001-07-12 US disclosed
EP-0736531-A1 Alpha-substituted pyridazino quinoline compounds ZENECA LIMITED (GB) 1996-10-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105389-A1 Macrocyclic Ghrelin Receptor Antagonists and Inverse Agonists and Methods of Using the Same GHSR, GHRHR, GIPR AKT1 3790/4885CTSS 2800/4885CTSL 2458/4885
US-20010007869-A1 ALPHA-SUBSTITTUTED PYRIDAZINO QUINOLINE COMPOUNDS CBR3, CHRNA1, CBR1 AKT1 3803/4885CTSS 3891/4885CTSL 4283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.